|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/573 | (2006.01) |
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 2637670 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11788077.3 |
| Date of filing the European patent application | 2011-10-27 | |
| (97) | Date of publication of the European application | 2013-09-18 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-08 |
| (46) | Date of publication of the claims translation | 2017-05-25 |
| (86) | Number | PCT/EP2011/068862 |
| Date | 2011-10-27 |
| (87) | Number | WO 2012/062596 |
| Date | 2012-05-18 |
| (30) | Number | Date | Country code |
| 412229 P | 2010-11-10 | US |
| (72) |
ZUGMAIER, Gerhard, DE
NAGORSEN, Dirk, DE
SCHEELE, Juergen, DE
|
| (73) |
Amgen Research (Munich) GmbH,
Staffelseestrasse 2, 81477 München,
DE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Nepageidaujamų poveikių, kuriuos sukelia prisijungimo domenai specifiški CD3, prevencija |
| PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS |
| Payment date | Validity (years) | Amount | |
| 2025-09-23 | 15 | 289.00 EUR |
| 2026-10-27 |